Directory Calendar News Careers Alumni Giving

Clareann H Bunker, PhD

Associate Professor Emeritus, Epidemiology

Download CV

Contact

A542 Crabtree, 130 Desoto Street, Pittsburgh, PA 15261
R-znvy: ohaxrep@cvgg.rqh
Primary Phone: 967-179-8912
Fax: 967-179-2842
Web site: http://www.edc.pitt.edu/epifaculty/faculty_bunker.asp

Assistant(s):

Marie Wilkerson, zjvyxref@cvgg.rqh, 967-179-8520

Personal Statement

Research Interests: Prostate cancer, ovarian cancer, molecular epidemiology, obesity, blood pressure, hypertension, diabetes, birth outcome.

Principal Investigator: Molecular Epidemiology of Prostate Cancer in Tobagonians (1999-2011) NCI, NIH; Inflammation and Ovarian Cancer (2009-2011) NCI, NIH; SHARE India University Pittsburgh Population and Intervention Research Training (2011-2016), Fogarty International Center, NIH; Empowering Indian Researchers with Computational Modeling Tools (2015-2018), Fogarty International Center, NIH

Education

1961 | Wellesley College, Wellesley, AB

1980 | Johns Hopkins University, Baltimore, MPH

1984 | University of Pittsburgh, Pittsburgh, PA | Epidemiology | PhD

1985 | University of Pittsburgh, Pittsburgh, PA | Epidemiology | Post-Doctoral Fellowship

Teaching

Co-taught Introduction to Molecular Epidemiology for 15 years

Selected Publications

Patrick AL, Bunker CH, Nelson JB, Dhir R, Wheeler VW, Zmuda JM, Richard JR, Belle AC, Kuller LH. Argument for prostate cancer screening in populations of African-Caribbean origin. BJU International. 2014 Jul 21. PMID:25046681. PMCID:PMC4406859. doi:10.1111/bju.12869.

Kurta ML, Moysich KB, Weissfeld JL, Youk AO, Bunker CH, Edwards RP, Modugno F, Ness RB, Diergaarde B. (2012, August). Use of fertility drugs and risk of ovarian cancer: results from a U.S-based case control study. Cancer Epidemiol Biomarkers Prev. 21(8):1282-92. Epub 2012 Jun 15. PMID: 22707710; PMCID:PMC3415595

Lo-Ciganic W-H, Zgibo JC, Bunker CH, Moysich KB, Edwards, RP, Ness RB. (2012, March) Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer. Epidemiology 2012; 23(2):311-19. PMID: 22252409; PMCID:PMC3454462

McDonald AC, Jenkins FJ, Bunker CH, Wilson JW, Patrick AL, Weissfeld JL. (2011, Dec). A case-cohort study of human herpesvirus 8 seropositivity and incident prostate cancer in Tobago. Infectious Agents and Cancer 2011; 6:25. PMID: 22151996; PMC3248833

Beason, T. S., Bunker, C. H., Zmuda, J. M., Wilson, J. W., Patrick, A. L., Wheeler, V. W., Weissfeld, J. L. (2011, May). ADRB2 gene variants, dual-energy x-ray absorptiometry body composition, and hypertension in Tobago men of African descent. Metabolism: clinical and experimental, 60(5), 698-705. PMCID: PMC2992095

Langevin, S. M., Stone, R. A., Bunker, C. H., Grandis, J. R., Sobol, R. W., Taioli, E. (2010, May). MicroRNA-137 promoter methylation in oral rinses from patients with squamous cell carcinoma of the head and neck is associated with gender and body mass index. Carcinogenesis, 31(5), 864-70. PMCID: PMC2864416

Farhat, G. N., Taioli, E., Cauley, J. A., Zmuda, J. M., Orwoll, E., Bauer, D. C., Wilt, T. J., Hoffman, A. R., Beer, T. M., Shikany, J. M., Daniels, N., Chan, J., Fink, H. A., Barrett-Connor, E., Parsons, J. K., Bunker, C. H., Osteoporotic Fractures in Men (MrOS) Study Group (2009, January). The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study. Cancer epidemiology, biomarkers & prevention : 18(1), 148-54. PMCID: PMC2651680

Okobia, M. N., Bunker, C. H., Garte, S. J., Zmuda, J. M., Ezeome, E. R., Anyanwu, S. N., Uche, E. E., Osime, U., Ojukwu, J., Kuller, L. H., Ferrell, R. E., Taioli, E. (2009). Cytochrome P450 1B1 Val432Leu polymorphism and breast cancer risk in Nigerian women: a case control study. Infectious agents and cancer, 4, S12. PMCID: PMC2638457

Shea, P. R., Ishwad, C. S., Bunker, C. H., Patrick, A. L., Kuller, L. H., Ferrell, R. E. (2008, March 1). RNASEL and RNASEL-inhibitor variation and prostate cancer risk in Afro-Caribbeans. The Prostate, 68(4), 354-9.

Bunker, C. H., McDonald, A. C., Evans, R. W., de la Rosa, N., Boumosleh, J. M., Patrick, A. L. (2007). A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutrition and cancer, 57(2), 130-7.

Bunker, C. H., Zmuda, J. M., Patrick, A. L., Wheeler, V. W., Weissfeld, J. L., Kuller, L. H., Cauley, J. A. (2006, October). High bone density is associated with prostate cancer in older Afro-Caribbean men: Tobago prostate survey. Cancer causes & control : CCC, 17(8), 1083-9.

Bunker, C. H., Patrick, A. L., Miljkovic-Gacic, I., Konety, B. R., Belle, A., Richard, J. R., Dhir, R. (2004, April). Prostate cancer screening parameters in a high-risk African-Caribbean population. Urology, 63(4), 737-41.

Hoffman, L. J., Bunker, C. H., Pellett, P. E., Trump, D. L., Patrick, A. L., Dollard, S. C., Keenan, H. A., Jenkins, F. J. (2004, January 1). Elevated seroprevalence of human herpesvirus 8 among men with prostate cancer. Journal of infectious diseases, 189(1), 15-20.

Shea, P. R., Ferrell, R. E., Patrick, A. L., Kuller, L. H., Bunker, C. H. (2002, October). ELAC2 and prostate cancer risk in Afro-Caribbeans of Tobago. Human genetics, 111(4), 398-400.

Bunker, C. H., Patrick, A. L., Konety, B. R., Dhir, R., Brufsky, A. M., Vivas, C. A., Becich, M. J., Trump, D. L., Kuller, L. H. (2002, August). High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev 11(8), 726-9.